Polar Asset Management Partners Inc. recently filed their 13F report for the third quarter of 2022, which ended on 2022-09-30.
The 13F report details which stocks were in a guru’s equity portfolio at the end of the quarter, though investors should note that these filings are limited in scope, containing only a snapshot of long positions in U.S.-listed stocks and American depository receipts as of the quarter’s end. They are not required to include international holdings, short positions or other types of investments. Still, even this limited filing can provide valuable information.
401 BAY STREET TORONTO, A6 M5H 2Y4
As of the latest 13F report, the guru’s equity portfolio contained 1355 stocks valued at a total of $6.82Bil. The top holdings were SRPT(1.52%), PHYS(1.12%), and SPY(1.02%).
According to GuruFocus data, these were Polar Asset Management Partners Inc.’s top five trades of the quarter.
North American Construction Group Ltd
During the quarter, Polar Asset Management Partners Inc. bought 1,045,948 shares of NYSE:NOA for a total holding of 3,155,115. The trade had a 0.19% impact on the equity portfolio. During the quarter, the stock traded for an average price of $12.44.
On 11/15/2022, North American Construction Group Ltd traded for a price of $13.25 per share and a market cap of $351.12Mil. The stock has returned -13.88% over the past year.
GuruFocus gives the company a financial strength rating of 4 out of 10 and a profitability rating of 7 out of 10.
In terms of valuation, North American Construction Group Ltd has a price-earnings ratio of 9.74, a price-book ratio of 1.66, a price-earnings-to-growth (PEG) ratio of 0.30, a EV-to-Ebitda ratio of 4.37 and a price-sales ratio of 0.82.
The price-to-GF Value ratio is 1.05, earning the stock a GF Value rank of 3.
Sarepta Therapeutics Inc
The guru established a new position worth 100,000,000 shares in NAS:SRPT, giving the stock a 1.52% weight in the equity portfolio. Shares traded for an average price of $100.79 during the quarter.
On 11/15/2022, Sarepta Therapeutics Inc traded for a price of $108.23 per share and a market cap of $9.50Bil. The stock has returned 27.42% over the past year.
GuruFocus gives the company a financial strength rating of 4 out of 10 and a profitability rating of 3 out of 10.
In terms of valuation, Sarepta Therapeutics Inc has a price-book ratio of 22.05, a EV-to-Ebitda ratio of -22.41 and a price-sales ratio of 10.76.
The price-to-GF Value ratio is 0.91, earning the stock a GF Value rank of 7.
iShares Expanded Tech-Software Sector ETF
The guru sold out of their 159,400-share investment in BATS:IGV. Previously, the stock had a 0.63% weight in the equity portfolio. Shares traded for an average price of $284.17 during the quarter.
On 11/15/2022, iShares Expanded Tech-Software Sector ETF traded for a price of $268.29 per share and a market cap of $4.78Bil. The stock has returned -39.45% over the past year.
There is insufficient data to calculate the stock’s financial strength and profitability ratings.
In terms of valuation, iShares Expanded Tech-Software Sector ETF has a price-earnings ratio of 39.38 and a price-book ratio of 5.88.
Lantheus Holdings Inc
The guru sold out of their 553,272-share investment in NAS:LNTH. Previously, the stock had a 0.54% weight in the equity portfolio. Shares traded for an average price of $75.74 during the quarter.
On 11/15/2022, Lantheus Holdings Inc traded for a price of $57.25 per share and a market cap of $3.94Bil. The stock has returned 88.07% over the past year.
GuruFocus gives the company a financial strength rating of 8 out of 10 and a profitability rating of 6 out of 10.
In terms of valuation, Lantheus Holdings Inc has a price-earnings ratio of 38.42, a price-book ratio of 6.18, a EV-to-Ebitda ratio of 17.62 and a price-sales ratio of 5.01.
The price-to-GF Value ratio is 1.75, earning the stock a GF Value rank of 1.
Abiomed Inc
The guru sold out of their 118,300-share investment in NAS:ABMD. Previously, the stock had a 0.43% weight in the equity portfolio. Shares traded for an average price of $270.04 during the quarter.
On 11/15/2022, Abiomed Inc traded for a price of $374.1 per share and a market cap of $16.87Bil. The stock has returned 3.66% over the past year.
GuruFocus gives the company a financial strength rating of 10 out of 10 and a profitability rating of 10 out of 10.
In terms of valuation, Abiomed Inc has a price-earnings ratio of 64.28, a price-book ratio of 10.97, a price-earnings-to-growth (PEG) ratio of 3.06, a EV-to-Ebitda ratio of 56.98 and a price-sales ratio of 15.98.
The price-to-GF Value ratio is 1.09, earning the stock a GF Value rank of 3.
Please note, the numbers and facts quoted are as of the writing of this article and may not factor in the latest trading data or company announcements.
Want to provide feedback on this article? Have questions or concerns? Get in touch with us here, or email us at [email protected]!
This article is general in nature and does not represent the opinions of GuruFocus or any of its affiliates. This article is not intended to be financial advice, nor does it constitute investment advice or recommendations. It was written without regard to your individual situation or financial goals. We aim to bring you fundamental, data-driven analysis, The information on this site is in no way guaranteed for completeness, accuracy or in any other way.
